Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-of-Illness Studies: An Updated Review of Current Methods.
Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Onukwugha E, et al. Among authors: varga s. Pharmacoeconomics. 2016 Jan;34(1):43-58. doi: 10.1007/s40273-015-0325-4. Pharmacoeconomics. 2016. PMID: 26385101 Review.
The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, Varga S, Herrera V, Ko JJ. Hua LH, et al. Among authors: varga s. J Manag Care Spec Pharm. 2019 Apr;25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. J Manag Care Spec Pharm. 2019. PMID: 30917079 Free PMC article.
At the time of this research, Morten and Kusel were paid employees of Costello Medical, which was contracted by Novartis to undertake some of this study's work. Lin, Cave, Herrera, and Ko were paid employees of Novartis at the time of this research. Cave, Herrera, and Ko a …
At the time of this research, Morten and Kusel were paid employees of Costello Medical, which was contracted by Novartis to undertake some o …
Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.
Djatche LM, Goble JA, Chun G, Varga S. Djatche LM, et al. Among authors: varga s. J Manag Care Spec Pharm. 2018 Jan;24(1):39-46. doi: 10.18553/jmcp.2018.24.1.39. J Manag Care Spec Pharm. 2018. PMID: 29290169 Free PMC article.
These regimens, used for second- or third-line treatment of RRMM, shared a common comparator in clinical trials: lenalidomide + dexamethasone (LEN + DEX). ASCO's 2016 VBF, which incorporated clinical benefit, toxicity, and bonus points, was used to generate a net health be …
These regimens, used for second- or third-line treatment of RRMM, shared a common comparator in clinical trials: lenalidomide + dexamethason …
495 results